Acceleron Pharma (XLRN) Gets a Hold Rating from Oppenheimer


In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Hold rating on Acceleron Pharma (NASDAQ: XLRN). The company’s shares closed yesterday at $43.65.

Cann wrote:

“Loss per share was $0.63 compared to our estimated loss of $0.57. The slightly higher than estimated loss was the result of R&D expenses of $25.9 million being 19.7% higher than our estimated $21.7 million. This was partially offset by higher estimated collaboration revenue.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 24.5% and a 55.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Currently, the analyst consensus on Acceleron Pharma is a Moderate Buy with an average price target of $54.43.

See today’s analyst top recommended stocks >>

The company has a one-year high of $50 and a one-year low of $31.80. Currently, Acceleron Pharma has an average volume of 456.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.

Read More on XLRN:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts